• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED IMMULITE 2000 XPI TOXOPLASMA QUANTITATIVE IGG (TXP); IMMULITE 2000 TOXOPLASMA QUANTITATIVE IGG (TXP)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED IMMULITE 2000 XPI TOXOPLASMA QUANTITATIVE IGG (TXP); IMMULITE 2000 TOXOPLASMA QUANTITATIVE IGG (TXP) Back to Search Results
Model Number N/A
Medical Device Problem Code False Positive Result (1227)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Type of Reportable Event Malfunction
Event or Problem Description
The customer observed discordant immulite 2000 xpi toxoplasma quantitative igg (txp) test results on three patient samples in comparison to an alternate method.Immulite 2000 xpi txp results for these samples were not reported to the physician, results from the alternate method were reported.There are no reports that treatment was altered or prescribed or adverse health consequences occurred due to the discordant immulite 2000 xpi toxoplasma quantitative igg (txp) results.
 
Additional Manufacturer Narrative
An outside of the united states (ous) customer contacted the siemens customer care center (ccc) to report discordant immulite 2000 xpi toxoplasma quantitative igg (txp) results when compared to an alternate method.The limitations section of the instructions for use states the following: "the results of the test must be taken within the context of the patient's clinical history, symptomology and other laboratory findings." siemens continues to investigate.
 
Additional Manufacturer Narrative
Siemens filed the initial mdr 1219913-2022-00312 on 22-september-2022.Siemens filed supplemental mdr 1219913-2022-00312-s1 on 03-january-2023.Additional information 21-feb-2023: siemens concluded the investigation for an outside of the united states (ous) customer observation of discordant immulite 2000 xpi toxoplasma quantitative igg (txp) results when using kit lot 517 in comparison to an alternate method.Field service engineer had checked the system and verified its performance.Siemens performed an investigation to determine if there had been a positive shift with immulite 2000 xpi txp kit lot 517.The investigation assessed internal data and customer data obtained from smart remote services (srs).Srs data was gathered and the percentage of samples resulting reactive, indeterminate, and non-reactive results for each kit lot was calculated.An increase in percent reactive results is not observed with immulite 2000 xpi txp kit lot 517.Based on internal panel data, interpretation variability for a single sample is observed historically.Review of the precision of the assay using immulite 2000 xpi txp kit lot 517 showed to be within specifications.Srs data and internal data do not confirm a positive shift in performance of immulite 2000 xpi txp kit lot 517.The investigation confirmed there has been no positive shift in performance for immulite 2000 xpi txp kit lot 517.Siemens cannot rule out pre-analytical factors such as sample handling or integrity, or sample specific effects as the cause of discordant results observed by the ous customer.The immulite 2000 xpi toxoplasma quantitative igg (txp) kit lot 517 is performing as intended.A product performance issue has not been identified.No further evaluation of the device is required.In section h6, the investigation findings and investigation conclusions codes were updated.
 
Additional Manufacturer Narrative
Siemens filed the initial mdr 1219913-2022-00312 on 22-september-2022.Additional information 21-december-2022: field service engineer had checked the system and verified its performance.Siemens initiated a study with immulite 2000 xpi toxoplasma quantitative igg (txp) lots 517, 519 and 520 with qc and patient samples, but the data was inconclusive.A second study was performed with txp lots 517, 520 and 521 (519 lot had expired) with qc and patient sample panel and noted high precision on some samples and different interpretations between lots.Further investigation is to be performed regarding this issue.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMMULITE 2000 XPI TOXOPLASMA QUANTITATIVE IGG (TXP)
Common Device Name
IMMULITE 2000 TOXOPLASMA QUANTITATIVE IGG (TXP)
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
glyn rhonwy
gwynedd, llanberis ll55 4el
UK 
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
glyn rhonwy
uk registration #: 3002806944
gwynedd, llanberis ll55 4el
UK  
Manufacturer Contact
karen babbitt
333 coney street
east walpole, MA 02032
3392069063
MDR Report Key15470004
Report Number1219913-2022-00312
Device Sequence Number4273936
Product Code LGD
UDI-Device Identifier00630414962238
UDI-Public00630414962238
Combination Product (Y/N)N
Initial Reporter CountryIT
PMA/510(K) Number
K962936
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Foreign,Health Professional,User Facility
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup,Followup
Report Date (Section B) 02/23/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date01/31/2023
Device Model NumberN/A
Device Catalogue Number10381323
Device Lot Number517
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Follow-Up
Initial Date Received by Manufacturer 09/12/2022
Supplement Date Received by Manufacturer12/21/2022
02/21/2023
Initial Report FDA Received Date09/23/2022
Supplement Report FDA Received Date01/03/2023
02/23/2023
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured03/08/2022
Is the Device Labeled for Single Use? (Y/N) No
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient SexUnknown
-
-